|
Akebia Therapeutics, Inc. (AKBA) Valoración de DCF |
Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
Predeterminadas Para Un Uso Rápido Y Eficiente
Compatible con MAC / PC, completamente desbloqueado
No Se Necesita Experiencia; Fáciles De Seguir
Akebia Therapeutics, Inc. (AKBA) Bundle
¡Simplifique la valoración de Akebia Therapeutics, Inc. (AKBA) con esta calculadora DCF personalizable! Con las finanzas reales de Akebia y las entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Akebia en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 295.3 | 213.6 | 292.6 | 194.6 | 160.2 | 143.4 | 128.4 | 115.0 | 102.9 | 92.2 |
| Revenue Growth, % | 0 | -27.68 | 37 | -33.49 | -17.7 | -10.46 | -10.46 | -10.46 | -10.46 | -10.46 |
| EBITDA | -341.0 | -226.0 | -43.3 | -6.9 | -13.7 | -65.1 | -58.3 | -52.2 | -46.7 | -41.8 |
| EBITDA, % | -115.47 | -105.8 | -14.78 | -3.53 | -8.57 | -45.38 | -45.38 | -45.38 | -45.38 | -45.38 |
| Depreciation | 33.6 | 36.1 | 35.3 | 37.6 | 36.8 | 23.7 | 21.2 | 19.0 | 17.0 | 15.2 |
| Depreciation, % | 11.37 | 16.92 | 12.06 | 19.33 | 22.94 | 16.52 | 16.52 | 16.52 | 16.52 | 16.52 |
| EBIT | -374.6 | -262.1 | -78.5 | -44.5 | -50.5 | -80.7 | -72.2 | -64.7 | -57.9 | -51.8 |
| EBIT, % | -126.85 | -122.71 | -26.84 | -22.86 | -31.51 | -56.24 | -56.24 | -56.24 | -56.24 | -56.24 |
| Total Cash | 268.7 | 149.8 | 90.5 | 42.9 | 51.9 | 70.7 | 63.3 | 56.7 | 50.7 | 45.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 26.9 | 51.6 | 41.1 | 39.3 | 34.4 | 25.5 | 22.8 | 20.4 | 18.3 | 16.4 |
| Account Receivables, % | 9.09 | 24.15 | 14.03 | 20.19 | 21.46 | 17.78 | 17.78 | 17.78 | 17.78 | 17.78 |
| Inventories | 61.0 | 38.2 | 21.8 | 15.7 | 16.2 | 18.4 | 16.5 | 14.8 | 13.2 | 11.8 |
| Inventories, % | 20.66 | 17.88 | 7.44 | 8.06 | 10.14 | 12.84 | 12.84 | 12.84 | 12.84 | 12.84 |
| Accounts Payable | 41.3 | 33.6 | 18.0 | 14.6 | 15.2 | 15.2 | 13.6 | 12.2 | 10.9 | 9.7 |
| Accounts Payable, % | 13.99 | 15.73 | 6.16 | 7.52 | 9.48 | 10.57 | 10.57 | 10.57 | 10.57 | 10.57 |
| Capital Expenditure | -.3 | -.1 | -.1 | .0 | .0 | -.1 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -0.10735 | -0.02762457 | -0.03896077 | 0 | -0.02060182 | -0.03890662 | -0.03890662 | -0.03890662 | -0.03890662 | -0.03890662 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -341.8 | -226.9 | -89.9 | -44.5 | -50.5 | -77.1 | -69.0 | -61.8 | -55.3 | -49.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -355.1 | -200.5 | -43.4 | -2.4 | -8.8 | -46.8 | -44.8 | -40.1 | -35.9 | -32.2 |
| WACC, % | 11.18 | 11.02 | 11.5 | 11.5 | 11.5 | 11.34 | 11.34 | 11.34 | 11.34 | 11.34 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -149.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -33 | |||||||||
| Terminal Value | -351 | |||||||||
| Present Terminal Value | -205 | |||||||||
| Enterprise Value | -355 | |||||||||
| Net Debt | -48 | |||||||||
| Equity Value | -307 | |||||||||
| Diluted Shares Outstanding, MM | 211 | |||||||||
| Equity Value Per Share | -1.45 |
What You Will Get
- Real AKBA Financial Data: Pre-filled with Akebia Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Akebia Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Akebia Therapeutics’ historical financial reports and projected forecasts.
- Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Calculations: Observe Akebia’s intrinsic value update instantly.
- Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable resource for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Akebia Therapeutics, Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Evaluate the outputs and leverage the results for investment decisions.
Why Choose Akebia Therapeutics, Inc. (AKBA)?
- Innovative Solutions: Pioneering therapies that address unmet medical needs in kidney disease.
- Proven Expertise: A team of industry leaders dedicated to advancing renal health.
- Commitment to Research: Continuous investment in clinical trials and scientific exploration.
- Patient-Centric Approach: Focused on improving patient outcomes and quality of life.
- Strong Partnerships: Collaborations with top research institutions and healthcare providers.
Who Should Use This Product?
- Investors: Accurately assess Akebia Therapeutics' fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Akebia Therapeutics (AKBA).
- Consultants: Effortlessly modify the template for valuation reports tailored to clients interested in Akebia Therapeutics (AKBA).
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies relevant to the biotechnology sector.
What the Template Contains
- Preloaded AKBA Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.